Renata Szymborska

Infusion billing's drug-cost and authorization complexity breaks general-purpose platforms.

Medicare and commercial payers are simultaneously squeezing 340B drug program margins.

Medicare cuts and IRA price negotiation will squeeze 340B margins starting in 2028.

Distinguish three benchmark types to avoid missing underpayments in infusion contracts.

Margin on infusion biologics hinges on managing product mix, authorizations, and billing precision.

CMS bundled rebate rules and 2028 MFP transitions will reshape infusion practice margins.

Manufacturer list-price cuts erode reimbursement margins for practices on WAC-based contracts.

Revenue per infusion exposes billing breakdowns that volume metrics mask.

Misclassifying vials costs practices through denials with no recovery path.

One denial on a five-figure drug claim can erase an entire month's margin for small infusion groups.